A Phase II Study Of PS-341 (VELCADE) In Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
Inclusion Criteria
DISEASE CHARACTERISTICS:
- Histologically confirmed diffuse large B-cell lymphoma, meeting criteria for 1 of the
following:
- Relapsed after prior high-dose chemotherapy with stem cell support
- Relapsed after prior chemotherapy, including at least 1 prior standard
non-Hodgkin's chemotherapy regimen, but not a candidate for high-dose
chemotherapy with stem cell support
- Measurable disease
- At least 1 bidimensionally measurable lesion at least 1.5 cm by CT scan
- No primary or secondary CNS lymphoma
- No HIV-related lymphoma
- No known brain metastases
PATIENT CHARACTERISTICS:
Age
- 18 and over
Performance status
- ECOG 0-2 OR
- Karnofsky 60-100%
Life expectancy
- More than 3 months
Hematopoietic
- Hemoglobin at least 9 g/dL
- Absolute neutrophil count at least 1,000/mm^3
- No colony-stimulating factors within 4 weeks before obtaining this result
- Platelet count at least 50,000/mm^3
- No platelet transfusion within 4 weeks before obtaining this result
Hepatic
- Bilirubin no greater than 2 times upper limit of normal (ULN)
- AST and ALT no greater than 2.5 times ULN
- No active hepatitis B or C viral infection
Renal
- Creatinine no greater than 2 times ULN OR
- Creatinine clearance at least 60 mL/min
Cardiovascular
- No myocardial infarction within the past 6 months
- No evidence of acute ischemia or new conduction system abnormalities on EKG
- No symptomatic congestive heart failure
- No unstable angina pectoris
- No cardiac arrhythmia
Other
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception
- Sodium greater than 130 mEq/L
- HIV negative
- No ongoing or active infection
- No other concurrent uncontrolled illness that would preclude study participation
- No psychiatric illness or social situation that would preclude study compliance
- No prior allergic reaction attributable to compounds of similar chemical or
biological composition to bortezomib
PRIOR CONCURRENT THERAPY:
Biologic therapy
- See Disease Characteristics
- See Chemotherapy
- At least 4 weeks since prior immunotherapy
Chemotherapy
- See Disease Characteristics
- More than 4 weeks since prior chemotherapy
- More than 12 weeks since prior high-dose chemotherapy with hematopoietic stem cell
support
Endocrine therapy
- Not specified
Radiotherapy
- More than 4 weeks since prior radiotherapy
- No concurrent radiotherapy
Surgery
- More than 4 weeks since prior major surgery unless fully recovered
Other
- Recovered from prior therapy
- No other concurrent investigational agents
- No other concurrent investigational or commercial agents or therapies to treat the
malignancy